Zhi Tong Cai Jing·2025-08-01 08:00Core Viewpoint - The collaboration between Borui Pharmaceutical and China Resources Sanjiu focuses on the development, registration, production, and commercialization of BGM0504 injection in mainland China, highlighting the potential of this innovative drug in treating various metabolic diseases [1] Group 1: Collaboration Details - Borui Pharmaceutical and its subsidiaries have signed a cooperation research agreement with China Resources Sanjiu for the exclusive development and commercialization of BGM0504 injection [1] - The agreement grants China Resources Sanjiu a non-transferable exclusive license for development and commercialization, specifically for collaboration with Borui Pharmaceutical and its affiliates [1] Group 2: Product Information - BGM0504 injection is a dual agonist of GLP-1 and GIP, classified as a first-class innovative chemical drug that has not yet been marketed domestically or internationally [1] - The drug aims to activate downstream pathways of GIP and GLP-1, demonstrating potential biological effects such as blood sugar control, weight loss, and treatment of non-alcoholic steatohepatitis (NASH) [1] Group 3: Development Status - Currently, BGM0504 injection is still in the research and development phase, requiring the completion of Phase III clinical trials and approval from the National Medical Products Administration before it can be produced and marketed [1]